Medically reviewed by Matthew Wosnitzer, MD Foamy pee may be a sign of proteinuria, a condition in which protein ...

Sibeprenlimab clinically reduces proteinuria in adults with immunoglobulin A nephropathy (IgAN), according to data from a prespecified analysis of the phase 3 VISIONARY trial presented during a ...

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Results from the study’s open-label period, presented at this year’s European Renal Association Congress, showed that ...

Empaveli reduced proteinuria by 68% versus placebo in glomerulopathy and glomerulonephritis, an effect that was sustained ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Everest Medicines presents positive results in preliminary analysis of phase 1b/2a trial of novel BTK inhibitor EVER001 at ERA 2025 Congress: Shanghai, China Tuesday, June 10, 202 ...

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving ...

Depending on more exact details of your kidney function (especially whether you are losing protein in your urine), ...